Table I.

Association between Gli1 expression and the clinical and pathological characteristics of patients with EOC.

		Gli1 expression				Nuclear Gli1 expression
Parameter	n	Positive	Negative	χ2	P-value	Positive	Negative	χ2	P-value
Age, years				0.752	0.386			0.411	0.734
<50	20	14	6			3	17
≥50	41	24	17			9	32
Tissue type				4.197	0.296			0.393	0.943
Serous	38	24	14			7	31
Mucinous	10	4	6			2	8
Endometrioid	10	7	3			2	8
Other	3	3	0			1	2
Stage				5.152	0.023			0.588	0.518
I–II	21	9	12			3	18
III–IV	40	29	11			9	31
Histological grade				1.340	0.247			1.605	0.309
G1	21	11	10			6	15
G2-G3	40	27	13			6	34
Lymph node metastasis				0.831	0.362			2.706	0.182
Yes	23	16	7			7	16
No	38	22	16			5	33
Platinum sensitivity				6.752	0.009			1.415	0.287
Resistant	17	15	2			5	7
Sensitive	44	23	21			12	37

Cytoplasmic expression of Gli1 is associated with the pathological surgical stage (χ²=5.152, P=0.023) and platinum resistance (χ²=6.752, P=0.009), whereas nuclear Gli1 expression is not significantly associated with any clinicopathological characteristics. EOC, epithelial ovarian cancer.